Person: Tannous, Bakhos
Email Address
AA Acceptance Date
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
First Name
Name
Search Results
Publication A chemical screen for medulloblastoma identifies quercetin as a putative radiosensitizer
(Impact Journals LLC, 2016) Lagerweij, Tonny; Hiddingh, Lotte; Biesmans, Dennis; Crommentuijn, Matheus H.W.; Cloos, Jacqueline; Li, Xiao-Nan; Kogiso, Mari; Tannous, Bakhos; Vandertop, W. Peter; Noske, David P.; Kaspers, Gertjan J.L.; Würdinger, Tom; Hulleman, EstherTreatment of medulloblastoma in children fails in approximately 30% of patients, and is often accompanied by severe late sequelae. Therefore, more effective drugs are needed that spare normal tissue and diminish long-term side effects. Since radiotherapy plays a pivotal role in the treatment of medulloblastoma, we set out to identify novel drugs that could potentiate the effect of ionizing radiation. Thereto, a small molecule library, consisting of 960 chemical compounds, was screened for its ability to sensitize towards irradiation. This small molecule screen identified the flavonoid quercetin as a novel radiosensitizer for the medulloblastoma cell lines DAOY, D283-med, and, to a lesser extent, D458-med at low micromolar concentrations and irradiation doses used in fractionated radiation schemes. Quercetin did not affect the proliferation of neural precursor cells or normal human fibroblasts. Importantly, in vivo experiments confirmed the radiosensitizing properties of quercetin. Administration of this flavonoid at the time of irradiation significantly prolonged survival in orthotopically xenografted mice. Together, these findings indicate that quercetin is a potent radiosensitizer for medulloblastoma cells that may be a promising lead for the treatment of medulloblastoma in patients.
Publication Functional Multiplex Reporter Assay Using Tagged Gaussia Luciferase
(Nature Publishing Group, 2013) van Rijn, Sjoerd; Nilsson, Jonas; Noske, David P.; Vandertop, W. Peter; Tannous, Bakhos; Würdinger, ThomasWe have developed a multiplex reporter system to monitor multiple biological variables in real-time. The secreted Gaussia luciferase was fused to ten different epitope tags (Gluc({tag})), each expressed in different tumor cells. By immunobinding of the tags followed by Gluc({tag}) detection, this system allowed the independent and real-time monitoring of mixed cell cultures in vitro and of mixed subcutaneous and intracranial tumor subpopulations in vivo.
Publication EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma
(Impact Journals LLC, 2014) Hiddingh, Lotte; Tannous, Bakhos; Teng, Jian; Tops, Bas; Jeuken, Judith; Hulleman, Esther; Boots-Sprenger, Sandra H.; Vandertop, W. Peter; Noske, David P.; Kaspers, Gertjan J.L.; Wesseling, Pieter; Wurdinger, ThomasGlioblastoma is the most common malignant primary brain tumor. Temozolomide (TMZ) is the standard chemotherapeutic agent for this disease. However, intrinsic and acquired TMZ-resistance represents a major obstacle for this therapy. In order to identify factors involved in TMZ-resistance, we engineered different TMZ-resistant glioblastoma cell lines. Gene expression analysis demonstrated that EFEMP1, an extracellular matrix protein, is associated with TMZ-resistant phenotype. Silencing of EFEMP1 in glioblastoma cells resulted in decreased cell survival following TMZ treatment, whereas overexpression caused TMZ-resistance. EFEMP1 acts via multiple signaling pathways, including γ-secretase-mediated activation of the Notch pathway. We show that inhibition of γ-secretase by RO4929097 causes at least partial sensitization of glioblastoma cells to temozolomide in vitro and in vivo. In addition, we show that EFEMP1 expression levels correlate with survival in TMZ-treated glioblastoma patients. Altogether our results suggest EFEMP1 as a potential therapeutic target to overcome TMZ-resistance in glioblastoma.
Publication Optical clearing and fluorescence deep-tissue imaging for 3D quantitative analysis of the brain tumor microenvironment
(Springer Netherlands, 2017) Lagerweij, Tonny; Dusoswa, Sophie A.; Negrean, Adrian; Hendrikx, Esther M. L.; de Vries, Helga E.; Kole, Jeroen; Garcia-Vallejo, Juan J.; Mansvelder, Huibert D.; Vandertop, W. Peter; Noske, David P.; Tannous, Bakhos; Musters, René J. P.; van Kooyk, Yvette; Wesseling, Pieter; Zhao, Xi Wen; Wurdinger, ThomasBackground: Three-dimensional visualization of the brain vasculature and its interactions with surrounding cells may shed light on diseases where aberrant microvascular organization is involved, including glioblastoma (GBM). Intravital confocal imaging allows 3D visualization of microvascular structures and migration of cells in the brain of mice, however, with limited imaging depth. To enable comprehensive analysis of GBM and the brain microenvironment, in-depth 3D imaging methods are needed. Here, we employed methods for optical tissue clearing prior to 3D microscopy to visualize the brain microvasculature and routes of invasion of GBM cells. Methods: We present a workflow for ex vivo imaging of optically cleared brain tumor tissues and subsequent computational modeling. This workflow was used for quantification of the microvasculature in relation to nuclear or cellular density in healthy mouse brain tissues and in human orthotopic, infiltrative GBM8 and E98 glioblastoma models. Results: Ex vivo cleared mouse brain tissues had a >10-fold imaging depth as compared to intravital imaging of mouse brain in vivo. Imaging of optically cleared brain tissue allowed quantification of the 3D microvascular characteristics in healthy mouse brains and in tissues with diffuse, infiltrative growing GBM8 brain tumors. Detailed 3D visualization revealed the organization of tumor cells relative to the vasculature, in both gray matter and white matter regions, and patterns of multicellular GBM networks collectively invading the brain parenchyma. Conclusions: Optical tissue clearing opens new avenues for combined quantitative and 3D microscopic analysis of the topographical relationship between GBM cells and their microenvironment. Electronic supplementary material The online version of this article (doi:10.1007/s10456-017-9565-6) contains supplementary material, which is available to authorized users.
Publication Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8
(Taylor & Francis, 2018) Berenguer, Jordi; Lagerweij, Tonny; Zhao, Xi Wen; Dusoswa, Sophie; van der Stoop, Petra; Westerman, Bart; de Gooijer, Mark C.; Zoetemelk, Marloes; Zomer, Anoek; Crommentuijn, Matheus H. W.; Wedekind, Laurine E.; López-López, Àlan; Giovanazzi, Alberta; Bruch-Oms, Marina; van der Meulen-Muileman, Ida H.; Reijmers, Rogier M.; van Kuppevelt, Toin H.; García-Vallejo, Juan-Jesús; van Kooyk, Yvette; Tannous, Bakhos; Wesseling, Pieter; Koppers-Lalic, Danijela; Vandertop, W. Peter; Noske, David P.; van Beusechem, Victor W.; van Rheenen, Jacco; Pegtel, D. Michiel; van Tellingen, Olaf; Wurdinger, ThomasABSTRACT Cancer cells release extracellular vesicles (EVs) that contain functional biomolecules such as RNA and proteins. EVs are transferred to recipient cancer cells and can promote tumour progression and therapy resistance. Through RNAi screening, we identified a novel EV uptake mechanism involving a triple interaction between the chemokine receptor CCR8 on the cells, glycans exposed on EVs and the soluble ligand CCL18. This ligand acts as bridging molecule, connecting EVs to cancer cells. We show that glioblastoma EVs promote cell proliferation and resistance to the alkylating agent temozolomide (TMZ). Using in vitro and in vivo stem-like glioblastoma models, we demonstrate that EV-induced phenotypes are neutralised by a small molecule CCR8 inhibitor, R243. Interference with chemokine receptors may offer therapeutic opportunities against EV-mediated cross-talk in glioblastoma.